Immunohistochemical analysis of the expression of the c-myc oncoprotein in human stomach cancers.
In an immunohistopathological study, we have used the specific monoclonal antibody myc 1-9E10 to the c-myc oncoprotein in 88 gastric carcinomas (22 gastric biopsies and 66 gastrectomies for cancer). Positive myc p62 immunoreactivity was shown in 48 (55%) cases with moderate or intense staining. The remaining 40 cases exhibited negative or equivocal staining. Normal stomach mucosa was generally nonreactive, with the exception of parietal cells. Elevated c-myc expression was not found to correlate with histological differentiation or in patients with metastases in one or more perigastric lymph nodes. A correlation was found between the level of c-myc expression and the stage of the disease, (p = 0.04); positive c-myc staining was found in 0/4 early gastric cancers and in 48/84 with advanced disease. Also, an association was found between the elevated c-myc expression and depth of invasion (p = 0.1; 0/4 mucosa and submucosa, 2/6 muscularis propria and 25/47 serosa). The c-myc monoclonal myc 1-9E10 may therefore be of use as a marker of advanced disease and depth of invasion in stomach cancer.